Best AAV / Gene Therapy CDMOs in Europe

Last updated: 2026-10-30 · updated as new inspection, certificate, and trial data enters the platform

← All AAV CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

153

EMA/MHRA GMP certs

For European-manufactured aav / gene therapy programs, Takeda, AGC Biologics, and Oxford Biomedica lead CDMO Signal's ranking of aav / gene therapy CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 52 scored aav / gene therapy CDMOs to 5 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.

Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 15 NAI (no action), 22 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (52), UNITED KINGDOM (36), United States (24), Germany (16), Austria (9).

Last updated 2026-10-30. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	TK Takeda Boston, MA · Zurich, CH	82.0	100.0	4 insp · 20 GMP	—	100 programs
2	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP Hiring · 35 open roles	78.5	99.8	4 insp · 27 GMP	Available	2 programs
3	OX Oxford Biomedica Oxford, United Kingdom Hiring · 9 open roles	76.2	100.0	2 insp · 13 GMP	Available	7 programs
4	Lonza Basel, Switzerland Hiring · 100+ open roles	72.8	86.5	11 insp · 8 GMP	—	1 programs
5	RT ReiThera Rome, IT	71.1	100.0	0 insp · 4 GMP	—	1 programs
6	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	86.3	99.2	9 insp · 11 GMP	Limited	0 programs
7	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK Hiring · 29 open roles	84.8	100.0	0 insp · 35 GMP	Expanding	0 programs
8	RP ReciBioPharm Keele, UK · Sodertalje, SE	82.9	100.0	0 insp · 3 GMP	—	0 programs
9	BR BioReliance (Merck) Glasgow, UK · Rockville, MD Hiring · 7 open roles	80.1	96.7	6 insp · 10 GMP	—	0 programs
10	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France. Hiring · 3 open roles	79.5	100.0	—	Available	0 programs
11	AA Ascend Advanced Therapies Rockville, MD · Alachua, FL · Munich, DE	78.1	100.0	0 insp · 1 GMP	—	0 programs
12	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
13	ET Exothera Jumet, BE	78.1	100.0	0 insp · 4 GMP	—	0 programs
14	PG ProBioGen Berlin, DE	78.1	100.0	0 insp · 4 GMP	—	0 programs
15	CE Celonic Basel, Switzerland Hiring · 4 open roles	78.1	100.0	0 insp · 1 GMP	—	0 programs
16	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
17	AD Advent Bioservices London, United Kingdom	78.1	100.0	0 insp · 2 GMP	—	0 programs
18	BV Biovian Turku, Finland	78.0	99.8	1 insp · 4 GMP	—	0 programs
19	VG Viralgen Vector Core San Sebastián, Spain Hiring · 3 open roles	76.8	100.0	0 insp · 4 GMP	Available	0 programs
20	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	65.5	—	—	—	0 programs
21	VE Rose BioSolutions Rockville, MD · Memphis, TN · Keele, United Kingdom	63.0	—	—	—	0 programs
22	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
23	AB Asklepios BioPharmaceutical (AskBio) Research Triangle, NC · San Sebastian, ES	61.8	—	—	—	10 programs
24	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
25	AM Anemocyte Gerenzano, Italy	59.0	—	—	—	0 programs
26	CV CEVEC Pharmaceuticals Cologne, Germany	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a AAV / Gene Therapy CDMO

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

AAV / Gene Therapy CDMOs — Frequently Asked Questions

Who are the top AAV / Gene Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Takeda, AGC Biologics, Oxford Biomedica. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many AAV / Gene Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 7 AAV / Gene Therapy CDMOs with FDA inspection records and 153 EMA/MHRA GMP certificates across the group.

What should I look for in an AAV CDMO?

Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.

What's the difference between AAV and lentiviral CDMOs?

AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.

Compare side-by-side

See two CDMOs' scoring, inspection history, and clinical footprint next to each other.

Open comparison →

Run a sourcing search

Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.

Search for a CDMO →

Save this AAV shortlist

Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.

Related modalities

Lentiviral Vector CDMOs Gene Editing CDMOs Plasmid DNA CDMOs

Other Modalities

CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector